Page last updated: 2024-11-05

thalidomide and Beckwith-Wiedemann Syndrome

thalidomide has been researched along with Beckwith-Wiedemann Syndrome in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Beckwith-Wiedemann Syndrome: A syndrome of multiple defects characterized primarily by umbilical hernia (HERNIA, UMBILICAL); MACROGLOSSIA; and GIGANTISM; and secondarily by visceromegaly; HYPOGLYCEMIA; and ear abnormalities.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
PLIESS, G1

Other Studies

1 other study available for thalidomide and Beckwith-Wiedemann Syndrome

ArticleYear
[Contribution to the teratological analysis of the new Wiedemann dysmelia syndrome (thalidomide abnormalities)].
    Medizinische Klinik, 1962, Sep-14, Volume: 57

    Topics: Abnormalities, Multiple; Beckwith-Wiedemann Syndrome; Hypnotics and Sedatives; Teratology; Thalidomi

1962